Search Results - "Benzinger, Tammie L.S"

Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease by Aschenbrenner, Andrew J, Gordon, Brian A, Benzinger, Tammie L.S, Morris, John C, Hassenstab, Jason J

“…OBJECTIVETo examine the independent and interactive influences of neuroimaging biomarkers on retrospective cognitive decline. METHODSA total of 152 middle-aged…”
Get full text

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease by Bateman, Randall J, Xiong, Chengjie, Benzinger, Tammie L.S, Fagan, Anne M, Goate, Alison, Fox, Nick C, Marcus, Daniel S, Cairns, Nigel J, Xie, Xianyun, Blazey, Tyler M, Holtzman, David M, Santacruz, Anna, Buckles, Virginia, Oliver, Angela, Moulder, Krista, Aisen, Paul S, Ghetti, Bernardino, Klunk, William E, McDade, Eric, Martins, Ralph N, Masters, Colin L, Mayeux, Richard, Ringman, John M, Rossor, Martin N, Schofield, Peter R, Sperling, Reisa A, Salloway, Stephen, Morris, John C

“…In this study of a cohort of adults with genetic mutations that cause autosomal dominant Alzheimer's disease, researchers identified abnormalities in…”
Get full text

Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later by Roe, Catherine M, Fagan, Anne M, Grant, Elizabeth A, Hassenstab, Jason, Moulder, Krista L, Maue Dreyfus, Denise, Sutphen, Courtney L, Benzinger, Tammie L.S, Mintun, Mark A, Holtzman, David M, Morris, John C

“…OBJECTIVES:We compared the ability of molecular biomarkers for Alzheimer disease (AD), including amyloid imaging and CSF biomarkers (Aβ42, tau, ptau181,…”
Get full text

Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study by Xiong, Chengjie, Jasielec, Mateusz S, Weng, Hua, Fagan, Anne M, Benzinger, Tammie L.S, Head, Denise, Hassenstab, Jason, Grant, Elizabeth, Sutphen, Courtney L, Buckles, Virginia, Moulder, Krista L, Morris, John C

“…OBJECTIVE:To determine whether and how longitudinal rates of change in MRI volumetrics, CSF concentrations of Alzheimer-related proteins, molecular imaging of…”
Get full text

Diffuse Microstructural Abnormalities of Normal-Appearing White Matter in Late Life Depression: A Diffusion Tensor Imaging Study by Shimony, Joshua S, Sheline, Yvette I, D'Angelo, Gina, Epstein, Adrian A, Benzinger, Tammie L.S, Mintun, Mark A, McKinstry, Robert C, Snyder, Abraham Z

“…Background Many recent studies have identified white matter abnormalities in late life depression (LLD). These abnormalities include an increased volume of…”
Get full text

Cross-sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology by Gordon, Brian A., McCullough, Austin, Mishra, Shruti, Blazey, Tyler M., Su, Yi, Christensen, John, Dincer, Aylin, Jackson, Kelley, Hornbeck, Russ C., Morris, John C., Ances, Beau M., Benzinger, Tammie L.S.

“…Structural magnetic resonance imaging is a marker of gray matter health and decline that is sensitive to impaired cognition and Alzheimer's disease pathology…”
Get full text

Preclinical Alzheimer's disease and longitudinal driving decline by Roe, Catherine M, Babulal, Ganesh M, Head, Denise M, Stout, Sarah H, Vernon, Elizabeth K, Ghoshal, Nupur, Garland, Brad, Barco, Peggy P, Williams, Monique M, Johnson, Ann, Fierberg, Rebecca, Fague, M. Scot, Xiong, Chengjie, Mormino, Elizabeth, Grant, Elizabeth A, Holtzman, David M, Benzinger, Tammie L.S, Fagan, Anne M, Ott, Brian R, Carr, David B, Morris, John C

“…Abstract Introduction Links between preclinical Alzheimer's disease (AD) and driving difficulty onset would support the use of driving performance as an…”
Get full text

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis by Schindler, Suzanne E, Bollinger, James G, Ovod, Vitaliy, Mawuenyega, Kwasi G, Li, Yan, Gordon, Brian A, Holtzman, David M, Morris, John C, Benzinger, Tammie L.S, Xiong, Chengjie, Fagan, Anne M, Bateman, Randall J

“…OBJECTIVEWe examined whether plasma β-amyloid (Aβ)42/Aβ40, as measured by a high-precision assay, accurately diagnosed brain amyloidosis using amyloid PET or…”
Get full text

Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease by Wang, Guoqiao, Li, Yan, Xiong, Chengjie, McDade, Eric, Clifford, David B., Mills, Susan L., Santacruz, Anna M., Aschenbrenner, Andrew J., Hassenstab, Jason, Benzinger, Tammie L.S., Gordon, Brian A., Fagan, Anne M., Coalier, Kelley A., Libre‐Guerra, Jorge J., McCullough, Austin, Joseph‐Mathurin, Nelly, Chen, Charles D., Mummery, Catherine, Wendelberger, Barbara A., Gauthier, Serge, Masellis, Mario, Holdridge, Karen C., Yaari, Roy, Chatterjee, Saptarshi, Sims, John, Delmar, Paul, Kerchner, Geoffrey A., Bittner, Tobias, Hofmann, Carsten, Bateman, Randall J.

“…Introduction While the Dominantly Inherited Alzheimer Network Trials Unit (DIAN‐TU) was ongoing, external data suggested higher doses were needed to achieve…”
Get full text

Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease by Joseph-Mathurin, Nelly, Su, Yi, Blazey, Tyler M., Jasielec, Mateusz, Vlassenko, Andrei, Friedrichsen, Karl, Gordon, Brian A., Hornbeck, Russ C., Cash, Lisa, Ances, Beau M., Veale, Thomas, Cash, David M., Brickman, Adam M., Buckles, Virginia, Cairns, Nigel J., Cruchaga, Carlos, Goate, Alison, Jack, Clifford R., Karch, Celeste, Klunk, William, Koeppe, Robert A., Marcus, Daniel S., Mayeux, Richard, McDade, Eric, Noble, James M., Ringman, John, Saykin, Andrew J., Thompson, Paul M., Xiong, Chengjie, Morris, John C., Bateman, Randall J., Benzinger, Tammie L.S.

“…18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is commonly used to estimate neuronal injury in Alzheimer's disease (AD). Here, we evaluate the…”
Get full text

Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease by McDade, Eric, Wang, Guoqiao, Gordon, Brian A, Hassenstab, Jason, Benzinger, Tammie L.S, Buckles, Virginia, Fagan, Anne M, Holtzman, David M, Cairns, Nigel J, Goate, Alison M, Marcus, Daniel S, Morris, John C, Paumier, Katrina, Xiong, Chengjie, Allegri, Ricardo, Berman, Sarah B, Klunk, William, Noble, James, Ringman, John, Ghetti, Bernardino, Farlow, Martin, Sperling, Reisa A, Chhatwal, Jasmeer, Salloway, Stephen, Graff-Radford, Neill R, Schofield, Peter R, Masters, Colin, Rossor, Martin N, Fox, Nick C, Levin, Johannes, Jucker, Mathias, Bateman, Randall J

“…OBJECTIVETo assess the onset, sequence, and rate of progression of comprehensive biomarker and clinical measures across the spectrum of Alzheimer disease (AD)…”
Get full text

Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging by Schindler, Suzanne E., Gray, Julia D., Gordon, Brian A., Xiong, Chengjie, Batrla-Utermann, Richard, Quan, Marian, Wahl, Simone, Benzinger, Tammie L.S., Holtzman, David M., Morris, John C., Fagan, Anne M.

“…Levels of amyloid β peptide 42 (Aβ42), total tau, and phosphorylated tau-181 are well-established cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease,…”
Get full text

White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network by Lee, Seonjoo, Viqar, Fawad, Zimmerman, Molly E., Narkhede, Atul, Tosto, Giuseppe, Benzinger, Tammie L.S., Marcus, Daniel S., Fagan, Anne M., Goate, Alison, Fox, Nick C., Cairns, Nigel J., Holtzman, David M., Buckles, Virginia, Ghetti, Bernardino, McDade, Eric, Martins, Ralph N., Saykin, Andrew J., Masters, Colin L., Ringman, John M., Ryan, Natalie S., Förster, Stefan, Laske, Christoph, Schofield, Peter R., Sperling, Reisa A., Salloway, Stephen, Correia, Stephen, Jack Jr, Clifford, Weiner, Michael, Bateman, Randall J., Morris, John C., Mayeux, Richard, Brickman, Adam M.

“…Objective White matter hyperintensities (WMHs) are areas of increased signal on T2‐weighted magnetic resonance imaging (MRI) scans that most commonly reflect…”
Get full text

Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions by Strain, Jeremy F, Smith, Robert X, Beaumont, Helen, Roe, Catherine M, Gordon, Brian A, Mishra, Shruti, Adeyemo, Babatunde, Christensen, Jon J, Su, Yi, Morris, John C, Benzinger, Tammie L.S, Ances, Beau M

“…OBJECTIVEWhite matter (WM) projections were assessed from Alzheimer disease (AD) gray matter regions associated with β-amyloid (Aβ), tau, or neurodegeneration…”
Get full text

AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure by Mishra, Shruti, Gordon, Brian A., Su, Yi, Christensen, Jon, Friedrichsen, Karl, Jackson, Kelley, Hornbeck, Russ, Balota, David A., Cairns, Nigel J., Morris, John C., Ances, Beau M., Benzinger, Tammie L.S.

“…Utilizing [18F]-AV-1451 tau positron emission tomography (PET) as an Alzheimer disease (AD) biomarker will require identification of brain regions that are…”
Get full text

Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage by Meeker, Karin L., Butt, Omar H., Gordon, Brian A., Fagan, Anne M., Schindler, Suzanne E., Morris, John C., Benzinger, Tammie L.S., Ances, Beau M.

“…Cerebrospinal fluid (CSF) neurofilament light chain (NfL) reflects neuro-axonal damage and is increasingly used to evaluate disease progression across…”
Get full text

Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels by Babulal, Ganesh M., O.T.D, Ghoshal, Nupur, M.D., Ph.D, Head, Denise, Ph.D, Vernon, Elizabeth K., B.A, Holtzman, David M., M.D, Benzinger, Tammie L.S., M.D., Ph.D, Fagan, Anne M., Ph.D, Morris, John C., M.D, Roe, Catherine M., Ph.D

“…Objectives To evaluate whether cerebrospinal fluid (CSF) and PET Pittsburgh Compound B (PiB) biomarkers of underlying Alzheimer disease (AD) pathology…”
Get full text

NIA-AA Staging of Preclinical Alzheimer Disease: Discordance and Concordance of CSF and Imaging Biomarkers by Vos, Stephanie J.B., PhD, Gordon, Brian A., PhD, Su, Yi, PhD, Visser, Pieter Jelle, MD, PhD, Holtzman, David M., MD, Morris, John C., MD, Fagan, Anne M., PhD, Benzinger, Tammie L.S., MD, PhD

“…Abstract The National Institute of Aging and Alzheimer’s Association (NIA-AA) criteria for Alzheimer disease (AD) treat neuroimaging and cerebrospinal fluid…”
Get full text

Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network by Bussy, Aurélie, Snider, B. Joy, Coble, Dean, Xiong, Chengjie, Fagan, Anne M., Cruchaga, Carlos, Benzinger, Tammie L.S., Gordon, Brian A., Hassenstab, Jason, Bateman, Randall J., Morris, John C.

“…The apolipoprotein E ε4 allele (APOE4) is the major genetic risk factor for sporadic Alzheimer's disease (AD). APOE4 may have effects on cognition and brain…”
Get full text

Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease by Schindler, Suzanne E., Li, Yan, Todd, Kaitlin W., Herries, Elizabeth M., Henson, Rachel L., Gray, Julia D., Wang, Guoqiao, Graham, Danielle L., Shaw, Leslie M., Trojanowski, John Q., Hassenstab, Jason J., Benzinger, Tammie L.S., Cruchaga, Carlos, Jucker, Mathias, Levin, Johannes, Chhatwal, Jasmeer P., Noble, James M., Ringman, John M., Graff-Radford, Neill R., Holtzman, David M., Ladenson, Jack H., Morris, John C., Bateman, Randall J., Xiong, Chengjie, Fagan, Anne M.

“…Four less well-studied but promising “emerging” cerebrospinal fluid (CSF) biomarkers are elevated in late-onset Alzheimer disease (AD): neurogranin,…”
Get full text